NASDAQ:NCNA NuCana - NCNA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. $0.85 +0.05 (+6.19%) (As of 03/28/2023 04:00 PM ET) Add Compare Share Share Today's Range$0.81▼$0.9150-Day Range$0.80▼$1.6952-Week Range$0.52▼$2.24Volume252,558 shsAverage Volume158,608 shsMarket Capitalization$44.50 millionP/E RatioN/ADividend YieldN/APrice Target$3.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media NuCana MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside329.9% Upside$3.67 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.53) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector436th out of 1,002 stocksPharmaceutical Preparations Industry204th out of 488 stocks 3.5 Analyst's Opinion Consensus RatingNuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, NuCana has a forecasted upside of 329.9% from its current price of $0.85.Amount of Analyst CoverageNuCana has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.28% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently increased by 55.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NCNA. Previous Next 1.7 News and Social Media Coverage News SentimentNuCana has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for NuCana this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NCNA on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added NuCana to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.53% of the stock of NuCana is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NuCana are expected to grow in the coming year, from ($0.53) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NuCana (NASDAQ:NCNA) StockNuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.Read More Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address NCNA Stock News HeadlinesMarch 24, 2023 | finance.yahoo.comTechnical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not ValidMarch 24, 2023 | finance.yahoo.comWe're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn RateMarch 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 14, 2023 | msn.comBank Stocks Boost European Equities Sharply Higher in Tuesday TradingMarch 13, 2023 | msn.comFinancial Stocks Weigh Down European Equities in Monday TradingMarch 9, 2023 | msn.comTelcoms Stocks Nudge European Equities Slightly Lower in Thursday TradingJanuary 3, 2023 | finance.yahoo.comNuCana to Host Investor Meetings During the J.P. Morgan Healthcare ConferenceDecember 20, 2022 | finance.yahoo.comNuCana plc (NCNA) Stock Historical Prices & Data - Yahoo FinanceMarch 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.November 16, 2022 | finance.yahoo.comNuCana Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 8, 2022 | finanznachrichten.deNuCana plc: NuCana to Present at the Jefferies London Healthcare ConferenceNovember 8, 2022 | finance.yahoo.comNuCana to Present at the Jefferies London Healthcare ConferenceOctober 26, 2022 | finance.yahoo.comNuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022October 15, 2022 | nz.finance.yahoo.comIs NuCana (NASDAQ:NCNA) In A Good Position To Deliver On Growth Plans?October 5, 2022 | nasdaq.comHere's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks - NasdaqOctober 3, 2022 | reuters.comNCNA.OQ - NuCana PLC (ADR) | Stock Price & Latest News | ReutersSeptember 28, 2022 | nasdaq.comNuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock? - NasdaqSeptember 28, 2022 | finance.yahoo.comDown 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA)September 23, 2022 | uk.investing.comWhy Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday By Benzinga - Investing.com UKSeptember 23, 2022 | seekingalpha.comNuCana Stock: An Intriguing 'Sum Of The Parts' Story (NASDAQ:NCNA) - Seeking AlphaSeptember 13, 2022 | finance.yahoo.comNuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 - Yahoo FinanceSeptember 12, 2022 | benzinga.comNuCana (NASDAQ:NCNA) – NuCana Presents Data On NUC-7738 At The European Society Of Medical Oncology Annua - BenzingaSeptember 12, 2022 | benzinga.comNuCana (NASDAQ:NCNA) – NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Onco - BenzingaSeptember 12, 2022 | globenewswire.comNuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 - GlobeNewswireSeptember 12, 2022 | finance.yahoo.comNuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022September 12, 2022 | finanznachrichten.deNuCana plc: NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022September 12, 2022 | finance.yahoo.comNuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address NCNA Company Calendar Last Earnings11/17/2021Today3/28/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NCNA CUSIPN/A CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees27Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.67 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+356.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,740,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.95% Return on Assets-43.49% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book0.46Miscellaneous Outstanding Shares52,180,000Free Float35,900,000Market Cap$41.91 million OptionableNot Optionable Beta1.29 Key ExecutivesHugh Stephen GriffithChief Executive Officer & Executive DirectorDonald MunozChief Financial OfficerElisabeth OelmannSenior VP-Medical & Clinical DevelopmentJeffrey D. BlossChief Medical OfficerTheresa Margaret BruceSenior Vice President-Clinical OperationsKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVAdageneNASDAQ:ADAGDecibel TherapeuticsNASDAQ:DBTXImmunomeNASDAQ:IMNMSCYNEXISNASDAQ:SCYXView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 61,137 shares on 2/14/2023Ownership: 0.117%Renaissance Technologies LLCSold 21,400 shares on 2/13/2023Ownership: 0.634%View All Institutional Transactions NCNA Stock - Frequently Asked Questions Should I buy or sell NuCana stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NCNA shares. View NCNA analyst ratings or view top-rated stocks. What is NuCana's stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price targets for NuCana's stock. Their NCNA share price forecasts range from $2.00 to $6.00. On average, they predict the company's share price to reach $3.67 in the next twelve months. This suggests a possible upside of 356.5% from the stock's current price. View analysts price targets for NCNA or view top-rated stocks among Wall Street analysts. How have NCNA shares performed in 2023? NuCana's stock was trading at $0.66 at the start of the year. Since then, NCNA stock has increased by 21.7% and is now trading at $0.8032. View the best growth stocks for 2023 here. Are investors shorting NuCana? NuCana saw a increase in short interest in March. As of March 15th, there was short interest totaling 118,000 shares, an increase of 55.5% from the February 28th total of 75,900 shares. Based on an average trading volume of 141,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.3% of the company's stock are short sold. View NuCana's Short Interest. When is NuCana's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our NCNA earnings forecast. How were NuCana's earnings last quarter? NuCana plc (NASDAQ:NCNA) posted its quarterly earnings data on Wednesday, November, 17th. The company reported ($15.00) earnings per share for the quarter, topping the consensus estimate of ($18.50) by $3.50. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Pfizer (PFE), Rigel Pharmaceuticals (RIGL) and Tetraphase Pharmaceuticals (TTPH). When did NuCana IPO? (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. What is NuCana's stock symbol? NuCana trades on the NASDAQ under the ticker symbol "NCNA." Who are NuCana's major shareholders? NuCana's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.63%) and Susquehanna International Group LLP (0.12%). How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NuCana's stock price today? One share of NCNA stock can currently be purchased for approximately $0.80. How much money does NuCana make? NuCana (NASDAQ:NCNA) has a market capitalization of $41.91 million. The company earns $-55,740,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. How can I contact NuCana? NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The official website for the company is www.nucana.com. The company can be reached via phone at 441313571111 or via email at chris.brinzey@westwicke.com. This page (NASDAQ:NCNA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.